Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
about
Targeted Therapies in Triple-Negative Breast CancerTargeting triple-negative breast cancer: optimising therapeutic outcomesGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsIncidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisSunitinib in solid tumorsPhase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast CancerPhase II study of sorafenib in patients with relapsed or refractory lymphoma.Phase II open-label study of sunitinib in patients with advanced breast cancer.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.New knowledge of the mechanisms of sorafenib resistance in liver cancerCombination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsThe best of both worlds - managing the cancer, saving the bone.Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Targeted Therapy in Breast Cancer.Present and future evolution of advanced breast cancer therapy.Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancerMinireview: Basal-like breast cancer: from molecular profiles to targeted therapiesThe effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.Promising molecular targeted therapies in breast cancerSorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenibA phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Triple-negative breast cancer: adjuvant therapeutic options.Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancerIdentification of new candidate therapeutic target genes in triple-negative breast cancerTargeting angiogenesis in metastatic breast cancerTargeted therapies in breast cancer: are heart and vessels also being targeted?Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewAntiangiogenic therapies in early-stage breast cancer.North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.Sorafenib in breast cancer treatment: A systematic review and overview of clinical trialsSkeletal metastasis: treatments, mouse models, and the Wnt signaling.Emerging targeted combinations in the management of breast cancer.Clinical overview of sorafenib in breast cancer.Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.
P2860
Q26777736-FF35C431-FBCF-4FE0-9F8A-DED7F450FF17Q26850892-0485A0B1-0B96-4150-9895-E2CF29A68AE5Q26998790-DF27BA9B-6861-4538-A0EC-F70C54D5DA45Q27003304-F40297D5-5F61-428B-90BB-F414396DA192Q28245467-6ADDACBF-4529-45B7-80BF-DCB2BFB6E01CQ28555102-C69066B7-9413-4341-B47F-77A61D44C4E9Q33401136-7AEF9088-3B68-466A-9974-B5393BECC6BBQ33403848-194C33CA-6D0F-47F0-BA68-BF91E1E37480Q33413742-F102D9B3-EB65-4E68-8C7C-8E9847F28AE3Q33415840-C0A76CE3-146E-486F-988A-AD9470D2FE2AQ33742211-2987679B-2FD1-4695-BB63-3615BAA41DCFQ33759933-0A3558C2-59DB-44A7-8A3F-C146333533F7Q33803564-F8FDDDA7-AA59-4E04-9CBA-D2C7753C51A0Q33920055-6B0AA337-F78E-457F-A3BB-B34E6B12C976Q34042709-10E2EB22-FBDF-46B4-A892-62C403C56222Q34096056-74AFFBAE-22C2-4EF8-89F8-F95344B90039Q34274925-E03F8322-E3E4-4EFD-8B6E-96D609C81A39Q34544166-D4EC8928-4216-41C3-8709-0466C90670A2Q34562257-95632E42-3EA0-4520-A8E2-6F2C674A4851Q34725749-78985E2E-E666-44E7-AA81-9AFF5B5A66A9Q35040295-6991AA27-0293-4545-8E87-B13EEE2B6241Q35190181-8A2385DB-0945-4524-800E-3F1D910C90E7Q35583678-B5D374C8-3B20-4C6E-9E29-1C6F7343308DQ35584239-7718538E-9B2D-4AF4-952C-8BF46259762CQ35599769-EF090ADA-DFA7-4B44-8EF1-C4CB58CCF3F4Q35692146-9BD7F960-B798-423A-81F7-BA6D3039CD3CQ35966791-B1D0BFAC-6979-4447-8891-612006996B17Q36153325-C857CC48-BC95-440A-B311-0F8A5B011502Q36182795-D2B4AA5B-8B9D-4D77-82F6-F2C7873D5A23Q36245324-A53C4B1B-0D60-4D43-88E8-F775564856FFQ36270115-76D06A7C-068C-4062-A0DB-413CCD5C8BF5Q36318210-4AE45E15-E2A3-45B7-B9BC-F9CF773F3BFDQ36652690-B4BD908F-86FA-473A-82B3-176EFB5872B8Q37048596-EF4A8937-3507-4B3A-8FB2-73D5FB88B866Q37129663-1767FFF7-48A6-4EDD-874E-E685082BD865Q37153297-F178B56A-58F1-42A0-B23B-AB0FCF7C4D36Q37354085-4B29646A-0855-46ED-B145-B3AA3D9D1985Q37593371-30D1CF4B-4113-42B8-9999-1FE66ADE2784Q37750770-50AD1C10-DF2E-4215-AD74-F3982E221074Q37863629-E26520D4-0A8B-43B4-A9DF-8D38B59A6EE1
P2860
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II trial of sorafenib in ...... p and Mayo Clinic Trial N0336.
@en
Phase II trial of sorafenib in ...... p and Mayo Clinic Trial N0336.
@nl
type
label
Phase II trial of sorafenib in ...... p and Mayo Clinic Trial N0336.
@en
Phase II trial of sorafenib in ...... p and Mayo Clinic Trial N0336.
@nl
prefLabel
Phase II trial of sorafenib in ...... p and Mayo Clinic Trial N0336.
@en
Phase II trial of sorafenib in ...... p and Mayo Clinic Trial N0336.
@nl
P2093
P2860
P356
P1476
Phase II trial of sorafenib in ...... p and Mayo Clinic Trial N0336.
@en
P2093
Alvaro Moreno-Aspitia
David W Hillman
Edith A Perez
Kendrith M Rowland
Martin Wiesenfeld
Patrick J Flynn
Roscoe F Morton
Tom R Fitch
Wilma L Lingle
P2860
P356
10.1200/JCO.2007.15.5242
P407
P577
2008-12-01T00:00:00Z